Skip to main content
SpringerLink
Log in

Management of Resistant Candida Infections

  • Chapter
Book cover Management of Multiple Drug-Resistant Infections

Part of the book series: Infectious Disease ((ID))

  • 133 Accesses

Abstract

The incidence of superficial and deep fungal infections has been steadily increasing during the last two decades because of an increased number of patients at risk for invasive fungal infections. Advances in therapeutic technology, the use of aggressive chemotherapy and immunosupression regimens, and the insertion of increasing numbers of intravascular devices account for this steady rise. Nosocomial candidiasis has risen more than threefold in the last decade, and Candida species are now the fourth most common cause of bloodstream infection in the United States (1). Systemic and deep organ fungal infections have become the leading causes of death among patients with hematological malignancies and among transplant recipients (2). Patients with acquired immunodeficiency syndrome (AIDS) are particularly at risk for fungal infections. Resistance of Candida species to antifungal agents has arisen because of a combination of the increased number of patients at risk, increased antifungal drug usage, and altered epidemiology of Candida infections.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in the United States Hospitals: a 3-year analysis. Clin Infect Dis 1999; 29: 239 - 244.

    Article  PubMed  CAS  Google Scholar 

  2. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781 - 805.

    Article  PubMed  CAS  Google Scholar 

  3. Lopez-Ribot JL, McAtee RK, Lee LN, et al. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus—infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 1998; 42: 2932 - 2937.

    PubMed  CAS  Google Scholar 

  4. Sanglard D, Kuchler K, Ischer F, et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378 - 2386.

    Article  PubMed  CAS  Google Scholar 

  5. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997; 41: 1482 - 1487.

    PubMed  CAS  Google Scholar 

  6. White TC, Marr KA, Bowden AR. Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin Microb Rev 1998; 11: 382 - 402.

    CAS  Google Scholar 

  7. Perea S, Lopez-Ribot JL, Kirkpatrick WR, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676 - 2684.

    Article  PubMed  CAS  Google Scholar 

  8. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002; 46: 1723 - 1727.

    Article  PubMed  CAS  Google Scholar 

  9. Rex JH, Pfaller MA, Galgiani JN, et al. Subcommittee on antifungal susceptibility testing of the National Committee for Clinical Laboratory Standards. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis 1997; 24: 235 - 247.

    Article  PubMed  CAS  Google Scholar 

  10. Sanglard D, Odds F. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis February 2002: 73 - 85.

    Google Scholar 

  11. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997. NCCLS document M27-A.

    Google Scholar 

  12. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microb Rev 2001; 14: 643 - 658.

    Article  CAS  Google Scholar 

  13. Rex JH, Pfaller MA, Barry AL, et al. Antifungal susceptibility testing of isolates from a randomised, multicentre trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidamia Study Group. Antimicrob Agents Chemother 1995; 39: 40 - 44.

    Article  PubMed  CAS  Google Scholar 

  14. Rex JH, Cooper WG, Merz JN, et al. Detection of amphotericin B resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995; 39: 906 - 909.

    Article  PubMed  CAS  Google Scholar 

  15. Nguyen MH, Clancy JC, Yu VL, et al. Do in vitro susceptibility data predict the microbio-logic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998; 177: 425 - 430.

    Article  PubMed  CAS  Google Scholar 

  16. Espinel-Ingroff A, Pfaller MA, Erwin ME, et al. Interlaboratory evaluation of E test method for testing antifungal susceptibilities of pathogenic yeast to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol 1996; 34: 848 - 852.

    CAS  Google Scholar 

  17. Pfaller MA, Messer SA, Karlsson A, et al. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J Clin Microbiol 1998; 36: 2586 - 2589.

    PubMed  CAS  Google Scholar 

  18. Arendrup M, Lundgren B, Jensen IM, et al. Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates. J Antimicrob Chemother 2001; 47: 521 - 526.

    Article  PubMed  CAS  Google Scholar 

  19. Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by Etest and response to therapy with amphotericin B: results from a multicentre prospective study of candidemia. Antimicrob Agents Chemother 1999; 43: 1289 - 1290.

    PubMed  CAS  Google Scholar 

  20. Peyron F, Favel A, Nguyen AM, et al. Improved detection of amphotericin B resistant isolates of Candida lusitaniae by Etest. J Clin Microbiol 2001; 39: 399 - 342.

    Article  Google Scholar 

  21. Pfaller MA, Messer SA, Bolstrom A. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B-enhanced ability to detect amphotericin B resistant Candida isolates. Diagn Microbiol Infect Dis 1998; 32: 223 - 227.

    Article  PubMed  CAS  Google Scholar 

  22. Warnock DW, Johnson EM, Rogers TR. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy. J Antimicrob Chemother 1998; 42: 321 - 331.

    Article  PubMed  CAS  Google Scholar 

  23. Cuenca-Estrella M, Lee-Yang W, Meral A, et al. Comparative evaluation of NCCLS M27-A and EUCAST Broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob Agents Chemother 2002: 46: 3644 - 3647.

    Article  PubMed  CAS  Google Scholar 

  24. Rex JH, Pfaller MA. Has antifungal susceptibility come of age? Clin Infect Dis 2002; 35: 982 - 989.

    Article  PubMed  CAS  Google Scholar 

  25. Pfaller MA, Diekema DJ, Jones RN, et al. Trends in antifungal susceptibility of Candida spp isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002; 40: 852 - 856.

    Article  PubMed  CAS  Google Scholar 

  26. Hoban DJ, Zhanel GG, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob Agents Chemother 1999; 43: 1463 - 1464.

    PubMed  CAS  Google Scholar 

  27. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40: 3551 - 3557.

    Article  PubMed  CAS  Google Scholar 

  28. St-Germain G, Laverdiere M, Pelletier R, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (19961998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001; 39: 949 - 953.

    Article  PubMed  CAS  Google Scholar 

  29. Kibbler CC, Seaton S, Barnes RA, et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 2003; 54: 18 - 24.

    Article  PubMed  CAS  Google Scholar 

  30. Safdar A, Chaturvedi V, Koll BS, et al. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonising strains and differences between isolates from three urban teaching hospital in New York City (Candida susceptibility trends study, 1998 to 1999). Antimicrob Agents Chemother 2002; 46: 3268 - 3272.

    Article  PubMed  CAS  Google Scholar 

  31. Pfaller MA, Diekema DJ, Jones N, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 36: 3254 - 3259.

    Article  Google Scholar 

  32. Ellis D. Amphotericin B: spectrum and resistance. Antimicrob Agents Chemother 2002; 49: 7 - 10.

    CAS  Google Scholar 

  33. Nolte FS, Parkinson T, Falconer DJ, et al. Isolation and characterisation of fluconazole and amphotericin B resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997; 41: 196 - 199.

    PubMed  CAS  Google Scholar 

  34. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 66 2678.

    Google Scholar 

  35. Barchiesi F, Arzeni D, Caselli F, et al. Primary resistance to flucytosine among clinical isolates of Candida spp. J Antimicrob Chemother 2000; 45: 408 - 409.

    Article  PubMed  CAS  Google Scholar 

  36. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of 5-fluorocytosine against 8803 clinical isolates of Candida spp: global assessment of primary resistance using National Committee for Clinical Laboratory Standards Susceptibility Testing methods. Antimicrob Agents Chemother 2002; 46: 3518 - 3521.

    Article  PubMed  CAS  Google Scholar 

  37. Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173: 219 - 225.

    Article  PubMed  CAS  Google Scholar 

  38. Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000; 30: 749 - 756.

    Article  PubMed  CAS  Google Scholar 

  39. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1070 - 1079.

    Article  Google Scholar 

  40. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274 - 1277.

    Article  PubMed  CAS  Google Scholar 

  41. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of C. krusei with fluconazole use. J Hosp Infect 2002; 50: 56 - 65.

    Article  PubMed  CAS  Google Scholar 

  42. Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122 - 1128.

    Article  PubMed  CAS  Google Scholar 

  43. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidaemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627 - 630.

    Article  PubMed  CAS  Google Scholar 

  44. Nguyen MH, Peacock JE, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617 - 623.

    Article  PubMed  CAS  Google Scholar 

  45. Paterson PJ, Whinney PHM, Potter M, Kibbler CC, et al. The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients. Br J Haem 2001; 112: 175 - 180.

    Article  CAS  Google Scholar 

  46. Chandra JC, Kuhn D, Mukherjee PK, et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture and drug resistance. J Bacteriol 2001; 183: 5385 - 5394.

    Article  PubMed  CAS  Google Scholar 

  47. Denning DW. Can we prevent azole resistance in fungi? Lancet 1995; 346: 454.

    Article  PubMed  CAS  Google Scholar 

  48. El-Din SS, Reynolds MT, Ashbee HR, et al. An investigation into the pathogenesis of vulvo-vaginal candidiosis. Sex Transm Infect 2001; 77: 179 - 183.

    Article  PubMed  CAS  Google Scholar 

  49. Mathema B, Cross E, Dun E, et al. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over the counter azole antifungal. Clin Infect Dis 2001; 33: 23 - 27.

    Article  Google Scholar 

  50. Dismukes W. Introduction to antifungal drugs. Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 653 - 657.

    Article  PubMed  CAS  Google Scholar 

  51. Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis 1997; 24: 776 - 784.

    Article  PubMed  CAS  Google Scholar 

  52. Sobel JD. Vaginitis. N Engl J Med 1997; 337: 1896 - 1903.

    Article  PubMed  CAS  Google Scholar 

  53. Denning DW. Fortnightly review: management of genital candidiasis. Working Group of the British Society for Medical Mycology. BMJ 1995; 310: 1241 - 1244.

    Google Scholar 

  54. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992; 14 (suppl. 1): S148 - S153.

    Article  PubMed  Google Scholar 

  55. Baily GG, Pery FM, Denning DW, et al. Fluconazole-resistant candidiosis in an HIV cohort. AIDS 1994; 8: 787 - 792.

    CAS  Google Scholar 

  56. Fichtenbaum CJ, Powderly WG. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis 1998; 26: 556 - 565.

    Article  PubMed  CAS  Google Scholar 

  57. Cartledge JD, Midgley J, Gazzard BG. Non-albicans oral candidiosis in HIV-positive patients. J Antimicrob Chemother 1999; 43: 419 - 422.

    Article  PubMed  CAS  Google Scholar 

  58. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27: 1291 - 1294.

    Article  PubMed  CAS  Google Scholar 

  59. Cassone A, De Bernardis F, Torosantucci A, et al. In vitro and in vivio anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180: 448 - 453.

    Article  PubMed  CAS  Google Scholar 

  60. Tacconelli E, Bertagnolio S, Posterar B, et al. Azole susceptibility patterns and genetic relationship among oral Candida strains isolated in the era of highly active antiretroviral therapy. J Acquir Immun Defic Syndr 2002; 31: 38 - 44.

    Article  CAS  Google Scholar 

  61. Barchiesi F, Maracci M, Radi B, et al. Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 2002; 50: 999 - 1002.

    Article  PubMed  CAS  Google Scholar 

  62. Johnson EM, Warnock DW. Azole drug resistance in yeasts. J Antimicrob Chemother 1995; 36: 751 - 755.

    Article  PubMed  CAS  Google Scholar 

  63. Ravenkar SG, Dib OP, Kirkpatrick WR, et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26: 960 - 963.

    Article  Google Scholar 

  64. Phillips P, Zemcov J, Mahmood W, et al. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996; 10: 1369 - 1376.

    CAS  Google Scholar 

  65. Cartledge JD, Midgley J, Youle M, et al. Itraconazole cyclodextrin solution effective treatment HIV-related candidiosis unresponsive to other azole therapy. J Antimicrob Chemother 1994; 33: 1071 - 1073.

    Article  PubMed  CAS  Google Scholar 

  66. Grim SA, Smith KM, Romanelli F, et al. Treatment of azole resistant oropharyngeal candidiasis with topical amphotericin B. Ann Pharmacother 2002; 36: 1383 - 1386.

    Article  PubMed  Google Scholar 

  67. Fichtenbaum CJ, Zackin R, Rajcic N, et al. Amphotericin B oral suspension for fluconazolerefractory oral candidiasis in persons with HIV infection. AIDS 2000; 14: 845 - 852.

    CAS  Google Scholar 

  68. Vazquez JA, Hidalgo JA, De Bono S. Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study. HIV Clin Trials 2000; 1: 23 - 29.

    Article  PubMed  CAS  Google Scholar 

  69. Villaneuva A, Gotuzzo E, Arathood EG, et al. A randomised double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294 - 299.

    Article  Google Scholar 

  70. Arathoon EG, Gotuzzo E, Noriega ML, et al. Randomised, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002; 46: 451 - 457.

    Article  PubMed  CAS  Google Scholar 

  71. Kartsonis N, DiNubile MJ, Bartizal K, et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immun Defic Syndr 2002; 31: 183 - 197.

    Article  CAS  Google Scholar 

  72. Ally R, Schurmann D, Kreisel W, et al. A randomised, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447 - 1454.

    Article  PubMed  CAS  Google Scholar 

  73. Hegener P, Troke PF, Fatkenheuer G, et al. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998; 12: 2227 - 2241.

    CAS  Google Scholar 

  74. Tortorano MA, Biraghi E, Astolfi A, et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 2002; 51: 297 - 304.

    Article  PubMed  CAS  Google Scholar 

  75. Edwards JE. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43 - 59.

    Article  PubMed  Google Scholar 

  76. Abbas J, Bodey GP, Hanna HA, et al. Candida krusei fungaemia. An escalating serious infection in immunocompromised patients. Arch Intern Med 2000; 17: 2659 - 2664.

    Article  Google Scholar 

  77. Gumbo T, Isada CM, Hall G, et al. Candida glabrata fungemia. Clinical features of 139 patients. Medicine (Baltimore) 1999; 78: 220 - 227.

    Article  CAS  Google Scholar 

  78. British Society for Antimicrobial Chemotherapy Working Party. Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 1994; 20: 522 - 528.

    Article  Google Scholar 

  79. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis and clinical disease with comparison to C. albicans. Clin Microb Rev 1999; 12: 80 - 96.

    Google Scholar 

  80. Hawkins JL, Baddour LM. Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis 2003; 36: 14 - 18.

    Article  Google Scholar 

  81. Minari A, Hachem R, Raad I. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. Clin Infect Dis 2001; 32: 186 - 190.

    Article  PubMed  CAS  Google Scholar 

  82. Leung AY, Chim CS, Ho PL, et al. Candida tropicalis fungaemia in adult patients with haematological malignancies: clinical features and risk factors. J Hosp Infect 2002; 50: 316 - 319.

    Article  PubMed  CAS  Google Scholar 

  83. Warn PA, Morrissey J, Moore CB, et al. In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. Antimicrob Agents Chemother 2000; 44: 2664 - 2671.

    Article  PubMed  CAS  Google Scholar 

  84. Sanati H, Belanger P, Fratti R, et al. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997; 41: 2492 - 2496.

    PubMed  CAS  Google Scholar 

  85. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998; 42: 3242 - 3244.

    PubMed  CAS  Google Scholar 

  86. Marco F, Pfaller MA, Messer S, et al. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 1998; 42: 161 - 163.

    Article  PubMed  CAS  Google Scholar 

  87. Pelletier R, Loranger L, Marcotte H, et al. Voriconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol 2002; 51: 479 - 483.

    PubMed  CAS  Google Scholar 

  88. Ghannoum MA, Okogbule-Wondi I, Bhat N, et al. Antifungal activity of voriconazole, fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. J Chemother 1999; 11: 34 - 39.

    PubMed  CAS  Google Scholar 

  89. Maesaki S, Hossain MA, Miyazaki Y, et al. Efficacy of FK463, a (1,3)-ß-D-glucan synthase inhibitor, in disseminated azole resistant Candida albicans infection in mice. Antimicrob Agents Chemother 2000; 44: 1728 - 1730.

    Article  PubMed  CAS  Google Scholar 

  90. Cuenca-Estrella M, Mellado E, Diaz-Guerra T, et al. Susceptibility of fluconazole-resistant clinical isolates of Candida spp to echinocandin LY 303366, itraconazole and amphotericin B. J Antimicrob Chemother 2000; 46: 475 - 477.

    Article  PubMed  CAS  Google Scholar 

  91. Moore CB, Oakley KL, Denning DW. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect 2001; 7: 11 - 16.

    Article  PubMed  CAS  Google Scholar 

  92. Bachmann SP. Patterson TF, Lopez-Ribot JL, et al. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 2002; 40: 2228 - 2230.

    Google Scholar 

  93. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326 - 2332.

    PubMed  CAS  Google Scholar 

  94. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin for invasive candidiasis. N Engl J Med 2002; 347: 2020 - 2029.

    Article  PubMed  CAS  Google Scholar 

  95. Pagano L, Mele L, Fianchi L, et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica 2002; 87: 535 - 541.

    PubMed  Google Scholar 

  96. Sora F, Chiusolo P, Piccirillo N, et al. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B. Clin Infect Dis 2002; 35: 1135 - 1136.

    Article  PubMed  Google Scholar 

  97. Conly J, Rennier R, Johnson J, et al. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J Infect Dis 1992; 165: 761 - 764.

    Article  PubMed  CAS  Google Scholar 

  98. Rokusz L, Liptay L, Kadar K. Successful treatment of chronic disseminated candidiasis with fluconazole and a granulocyte-macrophage colony-stimulating factor combination. Scand J Infect Dis 2001; 33: 784 - 786.

    Article  PubMed  CAS  Google Scholar 

  99. Poynton CH, Barnes RA, Rees J. Interferon gamma and granulocyte-macrophage colony stimulating factor for the treatment of hepatosplenic candidiosis in patients with acute leukemia. Clin Infect Dis 1998; 26: 239 - 240.

    Article  PubMed  CAS  Google Scholar 

  100. Kontoyiannis D, Lewis R. Antifungal drug resistance of pathogenic fungi. Lancet 2002; 359: 1135 - 1144.

    Article  PubMed  CAS  Google Scholar 

  101. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002; 35: 1073 - 1080.

    Article  PubMed  Google Scholar 

  102. Vazquez JA, Sobel JD, Demitriou R, et al. Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis 1994; 170: 1566 - 1569.

    Article  PubMed  CAS  Google Scholar 

  103. Dorrell L, Edwards A. Vulvovaginitis due to fluconazole resistant Candida albicans following self treatment with non-prescribed triazoles. Sex Transm Infect 2002; 78: 308 - 312.

    Article  PubMed  CAS  Google Scholar 

  104. Walker PP, Reynolds MT, Ashbee HR, et al. Vaginal yeasts in the era of over the counter antifungal. Sex Transm Infect 2000; 76: 437 - 438.

    Article  PubMed  CAS  Google Scholar 

  105. Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 1997; 24: 649 - 652.

    Article  PubMed  CAS  Google Scholar 

  106. Guaschino S, De Deat F, Sartore A, et al. Efficacy of maintenance therapy with topical boric acid comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2001; 184: 598 - 602.

    Article  PubMed  CAS  Google Scholar 

  107. White DJ, Habib AR, Vanthuyne A, et al. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infection. Sex Transm Infect 2001; 77: 212 - 213.

    Article  PubMed  CAS  Google Scholar 

  108. Singh S, Sobel JD, Bhargava P, et al. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002; 35: 1066 - 1070.

    Article  PubMed  Google Scholar 

  109. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beim Community Programs for Clinical Research in AIDS. Ann Intern Med 1997; 126: 689 - 196.

    PubMed  CAS  Google Scholar 

  110. Fitzgerald MR, Ahmed-Jushuf I, Radcliffe KW, et al. Clinical effectiveness group. Revised UK national guidelines on sexually transmitted infections and closely related conditions 2002. Sex Transm Infect 2002; 78: 81 - 82.

    Article  PubMed  CAS  Google Scholar 

  111. Fong IW. The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourin Med 1992; 68: 374 - 377.

    PubMed  CAS  Google Scholar 

  112. Spinillo A, Colonna L, Piazzi G, et al. Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. J Reprod Med 1997; 42: 83 - 87.

    PubMed  CAS  Google Scholar 

  113. Sobel JD, Kapernick PS, Zervos M, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001; 185: 363 - 369.

    Article  PubMed  CAS  Google Scholar 

  114. Han Y, Cutler JE. Antibody response that protects against disseminated candidiasis. Infect Immun 1995; 63: 2714 - 2719.

    PubMed  CAS  Google Scholar 

  115. Burnie JP, Lee W, Williams JD, et al. Control of an outbreak of systemic Candida albicans. BMJ (Clin Res Ed) 1985; 291: 1091 - 1093.

    Article  Google Scholar 

  116. Lupetti A, Tavanti A, Davini P, et al. Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol 2002; 40: 2363 - 2369.

    Article  PubMed  Google Scholar 

  117. Huang YC, Lin TY, Leu HS, et al. Outbreak of Candida parapsilosis fungemia in neonatal intensive care units: clinical implications and genotyping analysis. Infection 1999; 27: 97 - 102.

    Article  PubMed  CAS  Google Scholar 

  118. Boccia S, Poteraro B, La Sorda M, et al. Genotypic analysis by 27A DNA fingerprinting of Candida albicans isolated during an outbreak in neonatal intensive care unit. Infect Control Hosp Epidemiol 2002; 23: 281 - 284.

    Article  PubMed  Google Scholar 

  119. Fowler SL, Rhoton B, Springer SC, et al. Evidence for person to person transmission of Candida lusitaniae in a neonatal intensive care unit. Infect Control Hosp Epidemiol 1998; 19: 343 - 345.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Sanya Clements
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher C. Kibbler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Microbiology, Royal Free and University College Medical School, London, England

    Stephen H. Gillespie MD, FRCP, FRCPath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Clements, S., Kibbler, C.C. (2004). Management of Resistant Candida Infections. In: Gillespie, S.H. (eds) Management of Multiple Drug-Resistant Infections. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-738-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-738-3_16

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-438-8

  • Online ISBN: 978-1-59259-738-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation